⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

March 1, 2026ESMO rare cancers.Open Access

290P Sarcomatous transformation in germ cell tumors arises through early clonal divergence rather than linear progression

W-C. Wu C-C. Yen

View Full Paper

Ask AI

Bookmark

Share

Key Points

The aim is to investigate the emergence of sarcomatous transformation in germ cell tumors through clonal divergence.
Analysis of patient data treated with pimicotinib
Evaluation of adverse events and their duration
Clinical safety assessment of CSF-1R inhibitors
Pimicotinib treatment was associated with manageable and reversible toxicities.
Sustained antitumor activity with few treatment discontinuations due to adverse events.
Toxicities aligned with known effects of CSF-1R inhibitor class.

Implication

This analysis demonstrates a novel pathway in tumor progression, suggesting early divergence in germ cell tumors rather than linear growth.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Wu et al. (2026) studied this question.

synapsesocial.com/papers/69b2585696eeacc4fcec7db8 https://doi.org/10.1016/j.esmorc.2026.100215

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1292P Exploring HER3; A potentially targetable biomarker in rare metaplastic breast cancersClinical Trial · 2026
2291P Whole-body MRI screening for Li-Fraumeni syndrome: The Irish experienceClinical Trial · 2026
3Longer-term safety of pimicotinib in tenosynovial giant cell tumor (TGCT): Integrated analysis of phase 1 and phase 3 MANEUVER trial data.Human Clinical Trial · 2026
4Adverse events and their management in patients with tenosynovial giant cell tumor (TGCT) treated with pimicotinib, after longer-term follow-up from the global phase 3 MANEUVER trial.Late-Phase Clinical Trial · 2026
5Effect of pimicotinib on tumor response and physical function (PF) by tumor location in patients with tenosynovial giant cell tumor (TGCT): Results from the phase 3 MANEUVER trial.RCT · 2026

More related papers

Expert Perspectives on TGCT and the Outcomes of the Phase 3 MANEUVER Study of Pimicotinib Presented at ASCO and ESMO 2025: A Podcast Discussion2026
Pimicotinib versus placebo in tenosynovial giant cell tumor (TGCT): a plain language summary of the MANEUVER clinical trial2026
289P Manageable longer-term safety with the highly-selective colony stimulating factor-1 receptor (CSF-1R) inhibitor pimicotinib in patients with tenosynovial giant cell tumor (TGCT) in the global MANEUVER trial2026

More from ESMO rare cancers.

Prolonged disease control with trabectedin in metastatic EWSR1::PATZ1 sarcoma: a case reportMon,
A case of mucinous adenocarcinoma of the prostate: pathological complete response achieved with intensity-modulated radiation therapyMon,